CI-924对II型和IV型高脂蛋白血症患者血浆脂质的影响。
CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
作者信息
Corder C N, Kloer H U, Price M D
机构信息
Clinical Pharmacology Program, Oklahoma Medical Research Foundation, Oklahoma City.
出版信息
Eur J Clin Pharmacol. 1989;37(5):477-81. doi: 10.1007/BF00558127.
CI-924 (CI), 5,5'-[[1,1'-biphenyl]-2,5-diylbis(oxy)]bis[2,2- dimethylpentanoic acid] is chemically similar to gemfibrozil. Patients with Type II (n = 13) and Type IV (n = 22) hyperlipoproteinaemia (HLP) were maintained 12 weeks on a baseline diet containing 55% sugar, 15% protein 30% fat and less than 300 mg cholesterol daily to stabilize weight and lipids. They were then entered in a parallel group double-blinded protocol and received 0, 300, 600, or 1200 mg CI p.o. daily for 12 weeks. CI consistently elevated anti-atherogenic HDL and lowered VLDL at 600 mg/day in both Type II and Type IV HPL at 8 weeks. In Type II patients, CI lowered cholesterol, decreased LDL/HDL and increased ApoA-I. In Type IV patients, CI also lowered TC while elevating LDL and ApoA-II. CI had no effect on Apo-B, LDL-ApoB, or Apo-E.
CI-924（CI），即5,5'-[[1,1'-联苯]-2,5-二基双（氧基）]双[2,2-二甲基戊酸]，在化学结构上与吉非贝齐相似。患有II型（n = 13）和IV型（n = 22）高脂蛋白血症（HLP）的患者在含有55%糖、15%蛋白质、30%脂肪且每日胆固醇含量低于300毫克的基线饮食上维持12周，以稳定体重和血脂。然后他们进入平行组双盲方案，每天口服0、300、600或1200毫克CI，持续12周。在8周时，对于II型和IV型高脂蛋白血症患者，CI在每日600毫克剂量时持续升高抗动脉粥样硬化的高密度脂蛋白（HDL）并降低极低密度脂蛋白（VLDL）。在II型患者中，CI降低胆固醇，降低低密度脂蛋白/高密度脂蛋白比值并增加载脂蛋白A-I（ApoA-I）。在IV型患者中，CI也降低总胆固醇（TC），同时升高低密度脂蛋白（LDL）和载脂蛋白A-II（ApoA-II）。CI对载脂蛋白B（Apo-B）、低密度脂蛋白-载脂蛋白B（LDL-ApoB）或载脂蛋白E（Apo-E）没有影响。
Zotero 插件